DZ2169A1 - Nouveaux dérivés de 19-nor-prégnéne. - Google Patents

Nouveaux dérivés de 19-nor-prégnéne.

Info

Publication number
DZ2169A1
DZ2169A1 DZ970014A DZ970014A DZ2169A1 DZ 2169 A1 DZ2169 A1 DZ 2169A1 DZ 970014 A DZ970014 A DZ 970014A DZ 970014 A DZ970014 A DZ 970014A DZ 2169 A1 DZ2169 A1 DZ 2169A1
Authority
DZ
Algeria
Prior art keywords
pregnene
new derivatives
derivatives
new
Prior art date
Application number
DZ970014A
Other languages
English (en)
French (fr)
Inventor
Alain Piasco
Jean Lafay
Remi Delansorne
Jacques Paris
Jean-Claude Pascal
Original Assignee
Theramex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramex filed Critical Theramex
Application granted granted Critical
Publication of DZ2169A1 publication Critical patent/DZ2169A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ970014A 1996-01-22 1997-01-21 Nouveaux dérivés de 19-nor-prégnéne. DZ2169A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96400146A EP0785212A1 (en) 1996-01-22 1996-01-22 New 19-nor-pregnene derivatives

Publications (1)

Publication Number Publication Date
DZ2169A1 true DZ2169A1 (fr) 2002-12-25

Family

ID=8225217

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ970014A DZ2169A1 (fr) 1996-01-22 1997-01-21 Nouveaux dérivés de 19-nor-prégnéne.

Country Status (35)

Country Link
US (1) US6180803B1 (enExample)
EP (2) EP0785212A1 (enExample)
JP (2) JP4368945B2 (enExample)
KR (1) KR100396902B1 (enExample)
CN (1) CN1187366C (enExample)
AP (1) AP1176A (enExample)
AR (1) AR005500A1 (enExample)
AT (1) ATE184015T1 (enExample)
BR (1) BR9707064A (enExample)
CA (1) CA2243504C (enExample)
CO (1) CO4810230A1 (enExample)
CZ (1) CZ292047B6 (enExample)
DE (1) DE69700470T2 (enExample)
DZ (1) DZ2169A1 (enExample)
EE (1) EE03692B1 (enExample)
ES (1) ES2140961T3 (enExample)
GR (1) GR3031954T3 (enExample)
HU (1) HU221796B1 (enExample)
ID (1) ID15840A (enExample)
IL (1) IL125379A (enExample)
IS (1) IS1902B (enExample)
JO (1) JO1971B1 (enExample)
MY (1) MY116845A (enExample)
NO (1) NO309572B1 (enExample)
NZ (1) NZ330954A (enExample)
OA (1) OA10813A (enExample)
PE (1) PE55998A1 (enExample)
PL (1) PL185608B1 (enExample)
RU (1) RU2166509C2 (enExample)
SI (1) SI0886645T1 (enExample)
TN (1) TNSN97015A1 (enExample)
TR (1) TR199801399T2 (enExample)
TW (1) TW411345B (enExample)
WO (1) WO1997027210A1 (enExample)
ZA (1) ZA97521B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776191B1 (fr) * 1998-03-23 2002-05-31 Theramex Composition hormonale topique a effet systemique
TWI290549B (en) * 2000-06-02 2007-12-01 Astrazeneca Ab Process for the preparation of cyclopropyl carboxylic acid ester and derivatives
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
CA2418135C (en) 2000-08-03 2011-09-20 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
AU2004267956B2 (en) 2003-09-03 2010-09-16 Miscon Trading S.A. Methods for the treatment of endometriosis
CA2538856C (en) * 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US7425340B2 (en) 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US9173915B1 (en) * 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN109364020B (zh) * 2015-09-02 2021-12-28 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN110452279B (zh) * 2019-05-13 2022-04-08 株洲千金药业股份有限公司 三萜类化合物和其药学上可接受的盐及制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593524A1 (de) * 1951-01-28 1970-08-13 Schering Ag Verfahren zur Herstellung von 1,2alpha-Methylen-19-nor-steroiden
DE1087127B (de) * 1958-12-13 1960-08-18 Schering Ag Verfahren zur Herstellung neuer progestativ wirksamer Ester von 2-Methyl-Steroiden
FR1405214A (fr) * 1962-06-21 1965-07-09 Rhone Poulenc Sa Nouveaux stéroïdes de la série du prégnane et leur procédé de préparation
FR1525916A (fr) * 1965-11-09 1968-05-24 Schering Ag Stéroïdes portant un groupe méthylène en position 1.2 et leur préparation
US3891677A (en) * 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
US3835160A (en) * 1967-06-06 1974-09-10 Schering Corp 3{40 -keto-2{40 ,3{40 -seco-1{40 -(2{40 )-yne steroidal derivatives, methods for their manufacture, and compounds produced thereby
BE757286A (fr) * 1969-10-10 1971-04-09 Ciba Geigy Nouvelle 6alpha-methyl-19-nor progesterone et procede pour sa preparation
CH538462A (de) * 1970-10-07 1973-06-30 Ciba Geigy Ag Ein neues Verfahren zur Herstellung von 6a-Methyl-19-nor-pregnenen
DE3402330A1 (de) * 1984-01-20 1985-07-25 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha),2(alpha)-methylen-6-methylen- und 6(alpha)-methyl-pregnene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5395831A (en) * 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone

Also Published As

Publication number Publication date
DE69700470T2 (de) 2000-03-30
AR005500A1 (es) 1999-06-23
JP4368945B2 (ja) 2009-11-18
DE69700470D1 (de) 1999-10-07
CA2243504C (en) 2004-03-30
US6180803B1 (en) 2001-01-30
WO1997027210A1 (en) 1997-07-31
KR19990081895A (ko) 1999-11-15
IS4800A (is) 1998-07-21
BR9707064A (pt) 1999-12-28
NO309572B1 (no) 2001-02-19
ATE184015T1 (de) 1999-09-15
PL185608B1 (pl) 2003-06-30
IL125379A0 (en) 1999-03-12
KR100396902B1 (ko) 2004-05-03
CN1209811A (zh) 1999-03-03
JP2009167188A (ja) 2009-07-30
TR199801399T2 (xx) 1998-10-21
IL125379A (en) 2003-05-29
NO983356L (no) 1998-07-21
TW411345B (en) 2000-11-11
CZ292047B6 (cs) 2003-07-16
HUP9900684A3 (en) 1999-11-29
NZ330954A (en) 1998-10-28
GR3031954T3 (en) 2000-03-31
PL327998A1 (en) 1999-01-04
AU1595597A (en) 1997-08-20
TNSN97015A1 (fr) 2005-03-15
EP0785212A1 (en) 1997-07-23
AP9801299A0 (en) 1998-09-30
MY116845A (en) 2004-04-30
CN1187366C (zh) 2005-02-02
HK1018216A1 (en) 1999-12-17
ES2140961T3 (es) 2000-03-01
PE55998A1 (es) 1998-10-01
EP0886645A1 (en) 1998-12-30
AU708135B2 (en) 1999-07-29
RU2166509C2 (ru) 2001-05-10
HU221796B1 (hu) 2003-01-28
CZ230798A3 (cs) 1998-11-11
NO983356D0 (no) 1998-07-21
HUP9900684A2 (hu) 1999-07-28
EP0886645B1 (en) 1999-09-01
ID15840A (id) 1997-08-14
IS1902B (is) 2003-11-20
EE03692B1 (et) 2002-04-15
OA10813A (en) 2003-01-28
CA2243504A1 (en) 1997-07-31
EE9800219A (xx) 1998-12-15
AP1176A (en) 2003-06-30
ZA97521B (en) 1997-08-04
JP2000503980A (ja) 2000-04-04
SI0886645T1 (en) 1999-12-31
CO4810230A1 (es) 1999-06-30
JO1971B1 (en) 1997-12-15

Similar Documents

Publication Publication Date Title
BR9508247A (pt) Derivados de 2-arilciclopentano-2,3-dionas
PT901474E (pt) Derivados de aril-pirimidina.
PT934320E (pt) Derivados de naftiridina
PT891332E (pt) Derivados de 6-fenilpiridil-2-amina
DZ1961A1 (fr) Nouveaux composés.
DZ1989A1 (fr) Nouveaux composés.
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
EE9800227A (et) 17ß-karboksü-, karbotio- ja amiidandrostaanide laktoonderivaadid
IS1902B (is) Nýjar 19-nor-pregnene afleiður
PT921125E (pt) Derivados de 1,38-triaza-espiro 4,5 decan-4-ona
DE69732576D1 (de) Tetrahydrobenzindolon-derivate
BR9709065A (pt) Derivados de alquilaminobenzotiazole e-benzoxazol
MX224819B (es) Empleo cosmetico de derivados de bis(resorcinil)triacina.
PT922050E (pt) Derivados de 3-descladinose-2,3-anidroeritromicina
FR2727680B1 (fr) Nouveaux derives de 5-pyrrolyl-6-halogeno-2- pyridylmethylsufinylbenzimidazole
EP0739892A3 (de) Chromon-Derivate
FR2747121B1 (fr) Nouveaux derives de 2,3-benzodiazepine
PT906279E (pt) Derivados de pirrol
PT931087E (pt) Novos derivados de piranosido
ATE241599T1 (de) 25-hydroxy-16-ene-26,27-bishome-cholecalcerifer l derivate
MA26440A1 (fr) Derives de n-benzylazolium
BR9706702A (pt) Purificação de 1,1,1,3,3-pentafluorpropano
DK0810216T3 (da) Derivater af 10,11-dihydro-10-oxo-5H-dibenz/b/,f/azepin-5-carboxamid
PT796843E (pt) Derivados de 1,25-di-hidroxi-16,22,23-trisde-hidro-colecalciferol
ID16434A (id) Senyawa-senyawa 1,4-dihidropiridin